Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct 23;51(20):6495-502.
doi: 10.1021/jm8007486. Epub 2008 Sep 25.

Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships

Affiliations

Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships

Gary E L Brandt et al. J Med Chem. .

Abstract

Gedunin (1), a tetranortriterpenoid isolated from the Indian neem tree ( Azadirachta indica), was recently shown to manifest anticancer activity via inhibition of the 90 kDa heat shock protein (Hsp90) folding machinery and to induce the degradation of Hsp90-dependent client proteins similar to other Hsp90 inhibitors. The mechanism of action by which gedunin induces client protein degradation remains undetermined, however, prior studies have demonstrated that it does not bind competitively versus ATP. In an effort to further probe the mechanism of action, 19 semisynthetic derivatives of gedunin were prepared and their antiproliferative activity against MCF-7 and SkBr3 breast cancer cells determined. Although no compound was found to exhibit antiproliferative activity more effective than the natural product, functionalities critical for antiproliferative activity have been identified.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of GDA, gedunin (1), and novobiocin.
Figure 2
Figure 2
Western blot analysis of compounds 1, 3f, and 4 in SKBr3 breast cancer cells after 24 h of incubation at given concentrations.
Scheme 1<i><sup>a</sup></i>
Scheme 1a
a Reagents and conditions: (a) alkyl iodide, KOtBu, THF, 0°C; (b) propionyl chloride, DMAP, Et3N, CH2Cl2, 0 °C; (c) trichloroacetyl isocyanate, CH2Cl2; (d) PCC, CH2Cl2.
Scheme 2<i><sup>a</sup></i>
Scheme 2a
a Reagents and conditions: (a) NaOH, H2O2, acetone.
Scheme 3<i><sup>a</sup></i>
Scheme 3a
a Reagents and conditions: (a) NMO, OsO4, acetone, H2O, 0 °C; (b) 1,2-dimethoxypropane, pTsOH, acetone; (c) 10% Pd/C, MeOH; (d) NaBH4, CeCl3, MeOH/CHCl3; (e) iPrOH, Al(OiPr)3, toluene, 70 °C; (f) acyl chloride, DMAP, Et3N, CH2Cl2; (g) NaBH4, EtOH; (h) alkoxyamine hydrochloride, pyridine, 70 °C.
Scheme 4<i><sup>a</sup></i>
Scheme 4a
a Reagents and conditions: (a) hydroxylamine hydrochloride, pyridine, 70 °C.

References

    1. Borst P, Jonkers J, Roftenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007;6:2782–2787. - PubMed
    1. Nibili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7:861–879. - PubMed
    1. Duesberg P, Li R, Sachs R, Fabarius A, Upender M, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Updates. 2007;10:51–58. - PubMed
    1. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol, Res Pract. 1996;192:768–780. - PubMed
    1. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32:517–530. - PubMed

Publication types

MeSH terms